Les résultats et les conclusions des travaux menés par l’écosystème Experts Recherche Lymphome sont publiés dans des journaux médicaux de premier plan.
Lysa
2025_Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials.
Blood Cancer J 2025;15:190.
En savoir plus
Lysa
2025_Invasive Fungal Infections after CD19 CAR T-cell Therapy for B-Cell Lymphoma: a LYSA study from the DESCAR-T Registry
Clin Microbiol Infect 2025:S1198-743X(25)00502-6.
En savoir plus
Lysa
2025_Risk stratification of diffuse large B-cell lymphoma patients using plasma NMR-based metabolomics at diagnostic
Blood Adv 2025:bloodadvances.2025017248.
En savoir plus
Lysa
2025_Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy: A Descar-T Study By Lysa Group
Blood Adv 2025:bloodadvances.2025017234
En savoir plus
Lysa
2025_Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.
Blood Advances 2025
En savoir plus
Lysa
2025_An Individualized Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma.
NEJM Evid 2025;4:EVIDoa2500115
En savoir plus
Lysa
2025_Anti-CD19 CAR T-cell therapy for patients with Richter transformation: A LYSA study from the DESCAR-T registry.
Br J Haematol 2025;207:1143–7
En savoir plus
Lysa
2025_. Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment
Blood 2025;146:913–25.
En savoir plus
Lysa
2025_Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab Pharmacokinetics.
Clin Pharmacokinet 2025
En savoir plus
Lysa
2025_Impact of socioeconomic individual and ecological factors on extreme diagnosis-to-treatment interval in diffuse large B-Cell lymphoma in the French real-world cohort REALYSA.
Cancer Epidemiol 2025;98:102875
En savoir plus
Lysa
2025_Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II Study.
Blood Adv 2025:bloodadvances.2024015787
En savoir plus
Lysa
2025_IRF4 promotes immune evasion and shapes the tumor microenvironment in Follicular Lymphoma
Blood Cancer Discov 2025
En savoir plus
Lysa
2025_Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell Lymphoma.
Hematol Oncol 2025;43:e70117
En savoir plus
Lysa
2025-Synthetic Control Arm from Clinical Trial and Real-World Cohorts from Lysa Group for Untreated Older Classical Hodgkin Lymphoma for Innovative Clinical Trial Designs.
Hematological Oncology 2025;43:e371_70094.
En savoir plus
Lysa
2025_Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study
Blood Adv 2025;9:2266–74
En savoir plus
Lysa
2025_TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomas
Blood Adv 2025:bloodadvances.2025015834
En savoir plus
Lysa
2025_Investigating the Association Between a Continuous Variable and a Time-To-Event Outcome: Going Beyond the Cut-Off Approach
Hematol Oncol 2025;43:e70105.
En savoir plus
Lysa
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.
Br J Haematol 2025
En savoir plus
Lysa
2025_Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study
Blood Cancer J 2025;15:78
En savoir plus
Lysa
2025_Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV.
Bone Marrow Transplant
En savoir plus
Lysa
2025_Are oldest old patients with diffuse large B-cell lymphoma different than their younger counterparts: Results from the REALYSA real-life cohort
Cancer Epidemiol 2025;96:102812
En savoir plus
Lysa
2025_Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study
Nat Cancer 2025;:
En savoir plus
Lysa
2025_High-dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited-stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial
Hemasphere 2025;9:e70105
En savoir plus
Lysa
2025_Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA
EClinicalMedicine 2025;82:103157
En savoir plus